Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 11319557Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2026 award categories
- Pharmacology
- Internal Medicine
NIH Funding · FY2024
Linked Award Amount
$1.9M
Full award amounts, FY2024
Award Records
3
Records listing this PI
Award-Linked Rank
#5,700
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2024 award records by amount
NIH award records listing Jaume Padilla as a PI. Multi-PI records show the full award amount for context.
- 5R01HL151384-04R01Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes$667.9Kaward amount
- 5R01HL153264-04R01Role of neuraminidase activity on endothelial dysfunction in type 2 diabetes$646.2Kaward amount
- 1R01AG082413-01A1R01SGLT2 inhibition as a therapeutic strategy to reverse arterial stiffening in aging$617.7Kaward amount
Award organization
Organizations that administered FY2024 awards listing Jaume Padilla as a PI.
FY2024 award administered by University of Missouri-Columbia (MO).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardUniversity of Missouri-Columbia
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #5700
- 2025$2M Cumulative Funding
- 2025R01 Grant Holder
- 2026$5M Cumulative Funding
- 2026Entered Top 25% NationallyRanked #2816
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Jaume Padilla.